Status:
TERMINATED
Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
Lead Sponsor:
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Conditions:
Duchenne Muscular Dystrophy
Eligibility:
MALE
4+ years
Phase:
PHASE2
Brief Summary
To evaluate the long-term safety and tolerability of ACE-031 administration in subjects with Duchenne muscular dystrophy (DMD) who participated in Study A031-03. \[Note: This study was terminated base...
Eligibility Criteria
Inclusion
- Completion of participation in Study A031-03 and Investigator approval
- Continuation of corticosteroid therapy at the same absolute dose and schedule as on Study A031-03
Exclusion
- Participation in any other therapeutic clinical trial
- Plans to have surgery during the course of the study
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT01239758
Start Date
October 1 2010
End Date
May 1 2011
Last Update
February 1 2013
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Acceleron Investigative Site
Calgary, Alberta, Canada
2
Acceleron Investigative Site
Hamilton, Ontario, Canada
3
Acceleron Investigative Site
London, Ontario, Canada
4
Acceleron Investigative Site
Ottawa, Ontario, Canada